

**EXHIBIT C**  
**PENDING CLAIMS AFTER ENTRY OF THE AMENDMENT**

1. (Twice Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence as set forth in SEQ ID NO: 1;
- (b) a nucleotide sequence encoding the polypeptide set forth in SEQ ID NO: 2;
- (c) a nucleotide sequence complementary to either of (a) or (b).

2. (Twice Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding a polypeptide that is at least 95 percent identical to the polypeptide set forth in SEQ ID NO: 2, wherein the encoded polypeptide has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;
- (b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in SEQ ID NO: 1, encoding a polypeptide that has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;
- (c) a nucleotide sequence complementary to any of (a)-(b).

3. (Twice Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one conservative amino acid substitution, wherein the polypeptide has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;
- (b) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one amino acid insertion, wherein the polypeptide has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;

(c) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one amino acid deletion, wherein the polypeptide has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;

(d) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 which has a C- and/or N-terminal truncation, wherein the polypeptide has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;

(e) a nucleotide sequence encoding a polypeptide set forth in SEQ ID NO: 2 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has human E3 $\alpha$  ligase activity of the polypeptide set forth in SEQ ID NO: 2;

(f) a nucleotide sequence complementary to any of (a)-(e).

4. A vector comprising the nucleic acid molecule of claims 1, 2, or 3.

5. A host cell comprising the vector of claim 4.

6. The host cell of claim 5 that is a eukaryotic cell.

7. The host cell of claim 5 that is a prokaryotic cell.

8. A process of producing a huE3 $\alpha$  polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

10. The process of claim 8, wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native huE3 $\alpha$  polypeptide operatively linked to the DNA encoding the huE3 $\alpha$  polypeptide.

11. The isolated nucleic acid molecule according to claim 2 wherein the percent identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and the Smith-Waterman algorithm.

46. A composition comprising a nucleic acid molecule of claims 1, 2, or 3 and a pharmaceutically acceptable formulation agent.

47. A composition of claim 46 wherein said nucleic acid molecule is contained in a viral vector.

48. A viral vector comprising a nucleic acid molecule of claims 1, 2, or 3.

59. (Twice Amended) A reagent comprising a detectably labeled polynucleotide encoding the amino acid sequence set out in SEQ ID NO: 2; or allelic variants or spliced variants thereof with human E3 $\alpha$  ligase activity.

60. (Amended) The reagent of claim 59, wherein said labeled polynucleotide is a first-strand cDNA.

61. (Amended) A method for determining the presence of huE3 $\alpha$  nucleic acids in a biological sample comprising the steps of:

- (a) providing a biological sample suspected of containing huE3 $\alpha$  nucleic acids;
- (b) contacting the biological sample with a reagent according to claim 59 under conditions wherein the reagent will hybridize with huE3 $\alpha$  nucleic acids contained in said biological sample;
- (c) detecting hybridization between huE3 $\alpha$  nucleic acid in the biological sample and the reagent; and
- (d) comparing the level of hybridization between the biological sample and reagent with the level of hybridization between a known concentration of huE3 $\alpha$  nucleic acid and the reagent.

62. (Amended) A method for detecting the presence of huE3 $\alpha$  nucleic acids in a tissue or cellular sample comprising the steps of:

- (a) providing a tissue or cellular sample suspected of containing huE3 $\alpha$  nucleic acids;
- (b) contacting the tissue or cellular sample with a reagent according to claim 59 under conditions wherein the reagent will hybridize with huE3 $\alpha$  nucleic acids;
- (c) detecting hybridization between huE3 $\alpha$  nucleic acid in the tissue or cellular sample and the reagent; and
- (d) comparing the level of hybridization between the tissue or cellular sample and reagent with the level of hybridization between a known concentration of huE3 $\alpha$  nucleic acid and the reagent.

63. The method of claim 59 wherein said polynucleotide molecule is DNA.

64. The method of claim 59 wherein said polynucleotide molecule is RNA.